Early COVID-19 Vaccine Initiation and Completion Among Cancer Survivors and Barriers to Vaccine Completion: Implications for Future COVID-19 Vaccination Uptake Rates.
Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Nikta SaeediDepartment of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0009-0004-4327-1828
Angel ArizpeDepartment of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-4075-2675
Katelyn J QueenDepartment of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Jennifer TsuiDepartment of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Sue KimDepartment of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Brian Z HuangDepartment of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-8645-5142
Albert J FariasDepartment of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-6463-7831
Funding
Technology to Empower Changes in Health (TECH) Network Participant Technologies CenterU24OD023176 · OD · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2016 to 2022
$204.7M
Precision Medicine Initiative Cohort Program BiobankU24OD023121 · OD · MAYO CLINIC ROCHESTER · PI CEKANOVA, MARIA, CICEK, MINE · 2016 to 2024
$185.5M
Enhancing All of Us Data Resources for Nutrition Precision Health: the All of Us Data and Research CenterU2COD023196 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GLAZER, DAVID, HARRIS, PAUL A. · 2016 to 2022
$143.7M
Adaptive Platform for Personalized EngagementU24OD023163 · OD · VIGNET, INC. · PI JAIN, PRADUMAN · 2017 to 2020
$102.6M
University of Arizona-Banner Health All of Us Research Program OT2OD026549 · OD · UNIVERSITY OF ARIZONA · PI MORENO, FRANCISCO A, REIMAN, ERIC MICHAEL · 2018 to 2023
$78.9M
California Precision Medicine Research Program ConsortiumOT2OD026552 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ANTON-CULVER, HODA A, OHNO-MACHADO, LUCILA · 2018 to 2023
$73.4M
All of Us PennsylvaniaOT2OD026554 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E, VISWESWARAN, SHYAM · 2018 to 2023
$72.1M
New York City Consortium for Precision MedicineOT2OD026556 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BIER, LOUISE E, GHARAVI, ALI G · 2018 to 2023
$67.3M
SouthEast Enrollment Center (SEEC) OT2OD026551 · OD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI CARRASQUILLO, OLVEEN, COLON, VIVIAN · 2018 to 2023
$62.8M
Southern All of Us NetworkOT2OD026548 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FOUAD, MONA N., KORF, BRUCE R · 2018 to 2023
$60.5M
Illinois Precision Medicine Consortium OT2OD026557 · OD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI AHSAN, HABIBUL, ARGOS, MARIA · 2018 to 2023
$60.5M
The New England Precision Medicine Consortium of the All of Us Research ProgramOT2OD026553 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CLARK, CHERYL RENEE, KARLSON, ELIZABETH W · 2018 to 2023
$58.8M
National Institutes of Health Office of the Director 1 OT2 OD025276National Institutes of Health Office of the Director 1 OT2 OD025277National Institutes of Health Office of the Director 1 OT2 OD025337National Institutes of Health Office of the Director 1 OT2 OD026548National Institutes of Health Office of the Director 1 OT2 OD026549National Institutes of Health Office of the Director 1 OT2 OD026550National Institutes of Health Office of the Director 1 OT2 OD026551National Institutes of Health Office of the Director 1 OT2 OD026552National Institutes of Health Office of the Director 1 OT2 OD026553National Institutes of Health Office of the Director 1 OT2 OD026554National Institutes of Health Office of the Director 1 OT2 OD026555National Institutes of Health Office of the Director 1 OT2 OD026556National Institutes of Health Office of the Director 1 OT2 OD026557National Institutes of Health Office of the Director 1 UT4 OD023121National Institutes of Health Office of the Director 1 UT4 OD023163National Institutes of Health Office of the Director 3 OT025315National Institutes of Health Office of the Director 3 OT2 OD023205National Institutes of Health Office of the Director 3 OT2 OD023206National Institutes of Health Office of the Director 5 UTC OD023196National Institutes of Health Office of the Director HHSN 263201600085UNational Institutes of Health Office of the Director IAA #: AOD 16307NIH HHS OT2 OD023205NIH HHS OT2 OD023206NIH HHS OT2 OD025276NIH HHS OT2 OD025277NIH HHS OT2 OD025337NIH HHS OT2 OD026548NIH HHS OT2 OD026549NIH HHS OT2 OD026550NIH HHS OT2 OD026551NIH HHS OT2 OD026552NIH HHS OT2 OD026553NIH HHS OT2 OD026554NIH HHS OT2 OD026555NIH HHS OT2 OD026556NIH HHS OT2 OD026557NIH HHS U24 OD023121NIH HHS U24 OD023163NIH HHS U24 OD023176NIH HHS U2C OD023196ODCDC CDC HHS U24 OD023176
6 · The paper itself
Abstract
purposeCancer survivors are considered by public health officials as a high-risk group in the United States for severe complications from COVID-19. We aimed to characterize patterns of early uptake of the COVID-19 vaccine among cancer survivors and to determine modifiable barriers to vaccine completion that can be addressed to ensure future booster adherence.
methodsCross-sectional data of vaccine uptake by summer 2021 was extracted from adult cancer survivors enrolled in the "All of Us" research program. Vaccine completion was determined based on receiving at least two doses. We assessed sociodemographic factors, socioeconomic barriers (education, income, health insurance status, housing, and employment status), and COVID-19 vaccine uptake by Summer 2021, employing multivariable ordinal logistic regression for those who were unvaccinated, had initiated vaccine uptake, and had completed COVID-19 vaccination.
resultsOf the 514 cancer survivors in the sample, 73.7% were fully vaccinated by summer 2021. Those who received no vaccine doses showed higher proportions of SES barriers, medical distrust, and perceived lack of need barriers. Race (non-Hispanic White vs. other) was not statistically significantly associated with vaccine uptake (OR (95% CI) = 0.94 (0.51, 1.70)), while for every additional SES barrier, there was a 40% decrease (OR (95% CI) = 0.60 (0.48, 0.75)) in the odds of receiving more COVID-19 vaccine doses. Higher medical distrust and perceived lack of need were associated with 56% (OR = 0.44, 95% CI: 0.32-0.59) and 39% (OR = 0.61, 95% CI: 0.43-0.87) lower odds, respectively.
conclusionRacial/ethnic disparities in vaccine uptake may be explained by SES barriers. Addressing SES disparities and fostering medical trust may enhance future COVID-19 vaccination uptake rates for this high-risk group.
Indexed as
Cancer SurvivorsCOVID-19COVID-19 VaccinesAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedNeoplasmsSARS-CoV-2Socioeconomic FactorsUnited StatesVaccinationVaccination CoverageCOVID-19 VaccinesAll of Uscancer survivorshipCOVID‐19 vaccine
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Early COVID-19 Vaccine Initiation and Completion Among Cancer Survivors and Barriers to Vaccine Completion: Implications for Future COVID-19 Vaccination Uptake Rates. · full record | OpenQuestion